DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Proleukin (Aldesleukin) - Current Clinical Trials

 
 



Proleukin Related Clinical Trials

Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients [Recruiting]

Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy [Recruiting]

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... [Recruiting]

Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma [Recruiting]

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis [Completed]

A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients [Completed]

Interleukin 2, Aldesleukin and Entinostat for Kidney Cancer [Recruiting]

Aldesleukin With or Without Aflibercept in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery [Recruiting]

Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) [Recruiting]

Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases [Recruiting]

Vaccine Therapy and Aldesleukin in Treating Women With Metastatic Breast Cancer [Recruiting]

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma [Recruiting]

Autologous T Cells, Low-Dose Recombinant Interferon Gamma, Cyclophosphamide, and Low-Dose Aldesleukin in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery [Not yet recruiting]

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma [Not yet recruiting]

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage IV Melanoma [Recruiting]

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma [Recruiting]

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer [Recruiting]

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma [Recruiting]

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma [Recruiting]

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 [Recruiting]

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells [Recruiting]

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People [Recruiting]

Proleukin and Rapamune in Type 1 Diabetes [Recruiting]

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma [Recruiting]

IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma [Not yet recruiting]

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma [Recruiting]

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor [Not yet recruiting]

A Phase II Study Using Short-Term Cultured, CD8+-Enriched Autologous Tumor-infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers [Recruiting]

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma [Recruiting]

The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma [Recruiting]

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma [Recruiting]

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma [Terminated]

T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR) [Not yet recruiting]

Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2 [Recruiting]

Chemotherapy Followed By Autologous Natural Killer Cells and Aldesleukin in Treating Patients With Metastatic Melanoma or Kidney Cancer [Recruiting]

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Patients With Advanced Solid Tumors [Recruiting]

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3 [Active, not recruiting]

Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma [Recruiting]

Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer [Recruiting]

Laboratory-Treated T Cells With or Without Ipilimumab in Treating Patients With Metastatic Melanoma [Recruiting]

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant [Recruiting]

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma [Recruiting]

Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission [Active, not recruiting]

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer [Recruiting]

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer [Recruiting]

High-Dose Aldesleukin in Treating Patients With Metastatic or Unresectable Kidney Cancer [Recruiting]

Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients [Active, not recruiting]

Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer [Active, not recruiting]

A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Adesleukin for Human Papillomavirus-Associated Cancers [Recruiting]

Cyclophosphamide or Cellular Adoptive Immunotherapy With or Without Aldesleukin in Treating Patients With Metastatic Melanoma [Recruiting]

A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children [Active, not recruiting]

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML [Recruiting]

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma [Active, not recruiting]

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma [Suspended]

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma. [Completed]

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments [Completed]

Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma [Recruiting]

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia [Recruiting]

Aldesleukin in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer [Recruiting]

Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma [Recruiting]

Interferon-Gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma [Active, not recruiting]

Cyclophosphamide, Cellular Adoptive Immunotherapy, and Aldesleukin in Treating Patients With Metastatic Melanoma [Recruiting]

Chemotherapy Consisting of Fludarabine and Cyclophosphamide Followed By White Blood Cell Infusion, Vaccine Therapy, and Aldesleukin in Treating Patients With Recurrent or Refractory Metastatic Melanoma [Active, not recruiting]

Gene-Modified Lymphocytes, Cyclophosphamide, Fludarabine, and Aldesleukin in Treating Patients With Metastatic Cancer [Recruiting]

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer [Recruiting]

Laboratory-Treated Donor Natural Killer Cells and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Recurrent and/or Metastatic Ovarian Cancer [Recruiting]

Cyclophosphamide and Fludarabine Followed By Autologous Laboratory-Treated Peripheral Blood Lymphocytes and Aldesleukin in Treating Patients With Metastatic Melanoma [Recruiting]

Cyclophosphamide and Fludarabine Followed By White Blood Cell Infusion and High-Dose Aldesleukin in Treating Patients With Metastatic Cancer That Overexpresses p53 [Recruiting]

Gene-Modified T Lymphocytes With or Without Vaccine Therapy and/or Aldesleukin in Treating Patients With High-Risk Melanoma [Recruiting]

Chemotherapy and Total-Body Irradiation Followed By Autologous Lymphocyte Infusion, Aldesleukin, and Autologous Stem Cell Transplant in Treating Patients With Metastatic Melanoma [Suspended]

Cyclophosphamide and Fludarabine Followed By Laboratory-Treated Donor Lymphocytes and High-Dose Aldesleukin in Treating Patients With Metastatic Melanoma That Did Not Respond to Previous Treatment [Recruiting]

Cyclophosphamide and Fludarabine Followed By Autologous Gene-Modified Lymphocytes, Vaccine Therapy, and High-Dose Aldesleukin in Treating Patients With Metastatic Melanoma [Recruiting]

Cyclophosphamide and Fludarabine Followed By Vaccine Therapy, Autologous Gene-Modified Lymphocytes, and High-Dose Aldesleukin in Treating Patients With Metastatic Melanoma [Recruiting]

Cyclophosphamide or Denileukin Diftitox Followed By Laboratory-Treated T Cells in Treating Patients With HER2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER2/Neu Vaccine [Recruiting]

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone [Completed]

Adesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma [Recruiting]

Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases [Recruiting]

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin, and Umbilical Cord Blood Transplant in Treating Patients With Refractory Hematologic Cancers or Other Diseases [Recruiting]

Biochemotherapy With Temozolomide for Metastatic Melanoma [Recruiting]

Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy [Active, not recruiting]

Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia [Active, not recruiting]

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) [Active, not recruiting]

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer [Active, not recruiting]

Trastuzumab Plus Interleukin-2 in Treating Patients With Metastatic Breast Cancer [Active, not recruiting]

Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx [Recruiting]

The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex [Completed]

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma [Active, not recruiting]

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma [Completed]

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection [Not yet recruiting]

Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy [Active, not recruiting]

Combination Therapy With IL-2 Plus Antiretroviral Drugs to Treat HIV Infection [No longer recruiting]

Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults [Completed]

Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-Related Vasculitis Patients [Recruiting]

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

Effect of Interleukin-2 on HIV Treatment Interruption [Completed]

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer [Recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012